Vipivotide tetraxetan linker is primarily used in the development of targeted radiopharmaceuticals, particularly in prostate cancer treatment. It serves as a crucial component in conjugating radioactive isotopes to prostate-specific membrane antigen (PSMA) targeting molecules. This enables precise delivery of radiation to cancer cells, minimizing damage to surrounding healthy tissues. Its application is significant in diagnostic imaging and therapeutic interventions, enhancing the accuracy and efficacy of prostate cancer management. The linker’s stability and compatibility with radiolabeling processes make it a valuable tool in advancing nuclear medicine.